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TREATMENT FAILURE OF FALCIPARUM
MALARIA WITH FANSIDAR IN TAWAU SABAH,
JANUARY - JUNE, 1982
TAN HENG SOON
TAN PUAY ENG
SUMMARY
One hundred and ten consecutive patients with
falciparum malaria were treated with Fansidar and
primaquine. Ofthe 61 patients who were followed
up at one week, 4 (6.5%) failed to clear their
parasitemia (1 R IIIand 3 R Il treatmentfailures).
Ofthe subsequent 40 patients who were seen again
at one month, another 3 (7.5%) had recrudesced
(R 1 treatment failure). A total of 7 patients thus
experienced some form oftreatment failure in the
cohort of 40 who completed the one monthfollow
up. Only 1 ofthese 7patients (with R IIItreatment)
failure) failed to respond to repeat Fansidar
treatment, and may be the only one with true
Fansidar resistance. The overall treatment failure
rate of17.5% (95% confidence interval: 6-29%) in
the cohort who completed the study is consistent
with the known clinical efficacy ofFansidar. These
results suggest no significant Fansidar resistance in
falciparum malariafoundin Sabah.
INTRODUCTION
In the late seventies, clinical observers noted that
falciparum malaria in Sabah was increasingly
resistant to chloroquine treatment. I
In July 1978 to October 1979, an in vitro survey
using the method developed by Rieckmann 2 of 89
Tan Heng Soon, M.D.
Department of Medicine.
Tan Puay Eng, M.B.B.S.,
Department of Pathology,
Faculty of Medicine, University of Malaya,
Kuala Lumpur.
*. Fansidar (Roche}: sulfadoxine 500 mg + pyrimethamine 25 mg.
217
hospitalised patients with P. [alciparum. malaria in
8 of the 23 districts in Sabah revealed 87%
resistance ofthe parasite to chloroquine. 3
Consequently, the Department of Medical
Services of Sabah decided to switch to the use of
Fansidar* in the primary treatment of falciparum
malaria. 4
Increasing incidence of treatment failure to
Fansidar had been reported from Bangkok and
south-eastern Thailand where Fansidar had been in
use since the mid-seventies for primary
treatment. 5,6,7 Recently, case reports of Fansidar
treatment failure in Malaysia had also appeared. 8,9
Noting this with concern, we decided to monitor
the incidence of treatment failure to Fansidar in
patients with falciparum malaria since the drug was
adopted for primary treatment here 3 years ago.
METHODS
Eligibility
All consecutive clinic and ward patients with a
diagnosis of P. [alciparum at Tawau Hospital,
Sabah in the period January to June, 1982 were
studied.
Diagnosis
All febrile patients presenting to Tawau Hospital
had blood films taken and examined for malaria.
P. [alciparum was diagnosed on thick blood films.
Infection was excluded after examining 150
microscopic fields. Only asexual forms were
considered for inclusion in this study. Parasite
density was scored as follows, using a table modified
from Bruce-Chwatt: 10from those used In evaluating chloroquine
resistance: II
Statisticalanalysis
Statistical analysis of the patient characteristics
was performed using chi-square and analysis of
vanance.
RESULTS
Compliance
One hundred and thirteen patients were
diagnosed as having falciparum malaria at Tawau .
Hospital, Sabah in the period, January to June,
Patients who experienced initial R I and R II
treatment failure were treated using the initial drug
schedule and then followed up for a further one
month to complete the study.
Patients who failed retreatrnent with either a
persistence or recrudescence of parasitemia were to
be treated with oral quinine (30mg/kg/day in 3
divided doses) and tetracycline (250mg QID) for
one week. A further follow up of one month was to
be completed.
Patients with R III treatment failure were to be
treated with oral quinine and tetracycline straight
away and followed up for one month.
The following exceptions to the treatment
protocol were observed:
1. Patients with initial changes in mental status
(drowsiness, obtundation, and coma) were treated
as cerebral malaria with intravenous quinine
(10mg/kg every 12 hours) till improved, followed
by oral quinine (10mg/kg every 8 hours) for a total
of 14 days. These patients were excluded from
analysis.
2. Pregnant patients had primaquine and
tetracycline omitted.
3. Patients with haemolysis (by history or
examination)had primaquine omitted.
Recrudesced
PARASITEMIA IN THE
PERIOD BETWEEN
ONE WEEK TO ONE
MONTH FOLLOWING
DIAGNOSIS
Cleared
Diminished
Unchanged or
increased
PARASITEMIA
AT ONE WEEK
TREAT-
MENT
FAILURE
RI
RI!
RIII
AGE (yrs.)
DRUG: <1 1-4 5-9 10-14 15+
Fansidar tablet 1/4 1/2 1 2 3
Primaquine tablet 1 1+ 1/2 3 4 6
Followupandfurther treatment
The patients were reviewed one week and one
month after initial treatment. Patients were
considered cured if no persistence or reappearance
of asexual forms of falciparum malaria was
detected at the end of 28 days. Treatment failure
was classified as follows, using criteria modified
Initialtreatment
Single dose treatment with prepackaged Fansidar
tablets (sulfadoxine 500mg + pyrimethamine
25mg) and primaquine tablets (7.5mg) as a
gametocytoeidal agent was given by a nurse
according to the following schedule:
Questionnaire
Upon diagnosis and after examination by a
doctor, each patient was examined and quesioned
by a malaria field worker or laboratory technician
using a standardized questionnaire to elicit the
following information:
Patient profile in terms of age, sex, race, work
place and residence (in or outside Tawau, using city
limits).
Probable immune status, indirectly assessed by the
presence of a palpable spleen and a history of
previous malaria infection (since the tests for
malaria antibodies were not available).
Source of infection, ruling out imported infection
by determining the history of recent travel outside
the state within six months.
Severity of illness, by determining the duration of
illness before diagnosis and the initial density of
parasitemia at diagnosis.
Antecedent use ofanti-malarial drugs.
A methemoglobin reduction test was done on all
patients to determine the erythrocytic glucose-6-
phosphate dehydrogenase (G6PD) activity.
The patients were observed and the medications
were repeated if vomiting occurred within one hour
of drug administration. Patients were treated as
outpatients unless their clinical condition
warranted hospital admission. The determination
ofserum drug levels was not carried out because of
logistical problems
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ANALYSIS OF COMPLIANT AND DEFAULTED PATIENTS
PATIENTS WHO PATIENTS WHO PATIENTS WHO
CHARACTERISTICS
COMPLETED ONE COMPLETED ONE DEFAULTED ALL
WEEK FOLLOW UP MONTH FOLLOW UP FOLLOW UP
n = 61 (%) n = 40 (%) n = 49 (%) p value*
1. Sex:
Male: 48 (78.7) 32 (80.0) 42(85.7)
Female 13 (21.3) 8 (20.0) 7 (14.3) N.S.
2. Age, in years: 19.1 ± 13.1 18.8 ± 13.6 21.2 ± 10.9 N.S.
(mean ± 5.0.)
3. Race:
Bugis 20 (33.9) 13 (32.5) 20(40.8) N.S.
Suluk 2 (3.4) 2 (5.0) 5 (10.2) N.S.
Chinese 6 (10.2) 4 (10.0) 1(2.0) N.S.
Bajau 5 (8.5) 4 (10.0) 4 (8.2)
Kadazan 3 (51) 3 (7.5) 3 (6.1)
Murut 4 (6.8) 0(0.0) 0(0.0)
Others: ** 19 (32.2) 14 (35.0) 16 (32.7)
4. Residence
Outside Tawau: 35 (58.3)** 23 (59.0)** 31 (63.3)** N.S.
5. Past history ofmalaria: 23 (37.7) 15 (37.5) 15 (30.6) N.S.
Splenomegaly: 11 (18.0) 5 (12.5) ID (20.4) N.S.
Recent foreign travel
within 6 months: 2 (3.2) 1(2.5) 4 (8.1) N.S.
6. Duration ofillness, days: 3.5 ± 2.2 (a) 3.3 ± 2.1 (b) 3.9 ± 3.1 (c) N.S.
7. Antecedent use ofanti-
malaria drugs for the
present illness:
Chloroquine: 9 (14.8) 2 (5.0) 9 (18.4)
Fansidar: 11(18.0) 8 (20.0) 9(18.4) N.S.
Primaquine: ID (16.4) 8 (20.0) 8 (16.3)
8. Initial parasitemia:
(score range: 1 + to 4 +) 1.8 ± 0.9 1.9 ± 0.9 2.2 ± 1.0 N.S.
* Statistical test ofsignificance for all three columns
N.S. = not significant at the 5% level
** unavailable for 1 patient
(a), (b), (c): excludes 2 patients with more than 30 days of illness in each group, (a): excludes 5 patients, (b) excludes I patient, and
(c) excludes 6 patients with illness of uncertain duration.
1982. One died a week after diagnosis of chronic
uremic encephalopathy due to obstructive
uropathy. Two patients had cerebral malaria.
These 3 patients were not included in the analysis.
Ofthe remaining 110 patients, 61 (55.5%) had a
repeat blood film examined at one week.
Of these 61 patients, 40 (36.4%) completed the
one month follow up required in the study. All
these patients remained at home and returned to
the hospital for their periodic examination.
Patientprofile
Of the 61 patients who completed one week
follow up (see Table I), four-fifths were male,
around twenty years old, and a third of them were
Bugis. Over halfofthem were living and working in
plantations and timber camps outside Tawau. The
40 patients who went on to complete the one month
follow up were similar in all these aspects.
Only 38% had malaria previously and only 18%
had a palpable spleen on admission, suggesting that
219we are dealing with a fairly susceptible population
havingmalaria for the first time.
Very few (3%) had travelled outside the state
within six months, thus reducing the probability of
importedmalaria.
The mean duration of illness was short, viz. 3.5
days, except for two patients who complained of
illness for a period of more than one month before
diagnosis.
Again, there were no significant differences in
these respects between those who completed the one
week and onemonth follow up (see Table I).
Eleven patients had used Fansidar on their own
for the acute illness before diagnosis, and 10 of
them responded to the treatment protocol under
supervision. Only 1 patient who had used Fansidar
and primaquine for his acute illness before
diagnosis experienced R III treatment failure, and
did not respond to retreatment with the same
drugs.
The mean initial parasitemia, on a scoring scale
of 1+ to 4 + , was 1.8+, suggesting low parasite
density (in the region of 2000 parasites per cu.
mm).
Defaulters
The 49 patients (44.5%) who defaulted all follow
up were analysed as shown in Table 1. In regard to
the variables measured, they were not significantly
different from those who completed the study.
However, the defaulters tended to be foreign
migrant male workers from the more inaccessible
jungle areas presenting with slightly heavier
infections.
TreatmentFailure
One patient experienced R HI treatment failure
with unchanged parasitemia at the end of one
week. Three out of 61 patients failed to clear their
parasitemia one week after initial treatment, and
thus were classified as R H treatmentfailures.
Of the 40 patients who were examined at one
week and again at one month after initial
treatment, 33 had achieved radical cure. 4 had
failed to clear their parasitemia at one week (the
same 4 counted above) and another 3 developed
recrudescence in the period between one week and
one month of follow up, giving a total treatment
failure rate of 17.5% for this group. The 95%
confidence interval for this rate is between 6 to
29%.
Since the 3 patients with recrudescence had
returned to endemic malarial areas, some of these
recrudescences may in fact represent reinfections.
The overall treatment failure rate may be an over-
estimate.
Other ClinicalOutcome
All the patients with R I and R II treatment
failure responded successfully to a second course of
Fansidar (see Table I1). The one patient with R III
treatment failure was unfortunately not treated
according to protocol. He was inadvertently treated
with Fansidar and primaquine again (when in fact
quinine and tetracycline were indicated), and
failed to clear his parasitemia one week later.
Interestingly, chloroquine and proguanil were
administered (again out of protocol), with clinical
curel He remained parasite-free on follow up 28
days later.
No patient complained of any serious untoward
effects from the treatment regime. Four patients
had complete G6PD deficiency, but experienced no
hemolysis on treatment.
DIS.CUSSION
Tawau is a town on the south-eastern corner of
the state of Sabah adjacent to the border with
Indonesian Kalimantan. Of the population of
122,000 in the district ofTawau in 1980, 12 at least
20% was. estimated to consist of migrant
Indonesian workers employed in the cocoa and
oil-palm plantations and timber camps. These
workers working in and near newly cleared jungle
were especiallyvulnerable to malaria infections. 13
ENDEMICITY
Malaria is endemic in Tawau district, especially
in the timber camps and newly established
plantations. In 1982, the local Malaria Office
reported a total of 1470 malaria cases, of which
40% were in migrant workers. As shown in this
study, most of the malaria cases were contracted
locally.
TREATMENT FAILURE
Clinical reports in the early seventies noted the
presence of chloroquine resistance in P. [alciparurn.
infection around Tawau. 1
In 1973, a strain of P. [alciparum was isolated
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DETAILS OF PATIENTS WHO FAILED TO RESPOND TO FANSIDAR
R
III
Il
**
***
Age Sex Duration Initial Parasitemia Follow up period Density of Further follow up
yrs of illness parasitemia at Day 7 :t (from Day 0) parasitemia period (days)
in days at Day 0 before recurrence free of parasite
17 M >30 + + ** 16 *** + 28
29 M 3 ++ + ** 0 0 28
6M 1 ++ + ** 0 0 30
17 M 1 ++ + ** 0 0 30
23 F 7 ++ NA 12 ** ++ 14
22 F 2 ++ NA 14 ** ++ 28
5M 7 ++ 0 26 ** + 7
Treated with Fansidar and primaquine as described in the protocol
Treated with chloroquine and proguanil, out of protocol
R = Type of treatment failure, Sex: M = male, F = female, Duration of illness in days before diagnosis, Follow up period in days
(from Day 0) before recurrence of parasitemia, Density of parasitemia at the time of recurrence
NA = not available, 0 = absent
from a patient in Beaufort which exhibited in vitro
resistance to chloroquine, 14
In 1978, an initial epidemiological survey to
assess this problem of drug resistance was
attempted. In vitro testing of 20 P. falciparum
strains at Keningau showed a chloroquine
resistance rate of75%. 3
Further in vitro testingfromJuly 1978 to October
1979 of another 89 cases yielded a chloroquine
resistance rate of 38.6%. 3 These cases were mainly
collected on the west coast, except for 12 cases from
Tawau on the east coast ofwhich 11 were resistant.
These field surveys suffered from several
weaknesses:
1. Case selection was unspecified. It is not clear
whether these cases represented a population at
higher risk for chloroquine-resistant P. falciparum,
2. Because of technical problems, these 89 cases
represented only 61% ofthe actual number ofcases
tested.
Another one may conclude that chloroquine
resistance existed in Sabah in 1978, the extent and
degree ofresistance were not firmly established.
Subsequent in vitro testing continued into 1981
giving a cumulative total of 211 cases over the
period 1978-81. 135 tests (64%) were successful of
which 109 (81 %) were resistant. 15 This studyis also
subject to similar criticisms cited above.
In any case, in June 1979, the Malaria Control
Programme in Sabah switched from the use of
chloroquine to Fansidar in the treatment of
uncomplicated falciparum malaria. The
introduction of Fansidar as the primary medical
treatment for falciparum malaria was made not
without misgivings. Thailand had been using
Fansidar extensively in the treatment offalciparum
malaria since the mid-seventies. One series from
Bangkok 5 showed an increase of treatment failure
with Fansidar from a rate of 15-18% in 1975-76 to
48% by 1977-78. In 1982, another report from the
Thai-Khmer border 6 showed complete failure of
Fansidar to eradicate falciparum malaria
contracted by Thai soldiers who had been on
continuous Fansidar prophylaxis. This alarming
trend confirms the fear that the continuous use of
single drug treatment for prophylaxis and
treatment will yield drug resistance. 7
Case reports of treatment failure to Fansidar in
Malaysia had recently appeared. Three children
from an aboriginal family failed to respond to
Fansidar despite repeated treatment. 8 A
Vietnamese refugee with falciparum malaria
probably acquired in Mersing, johor, had R III
treatment failure to Fansidar despite adequate
drug absorption and elimination. 9
However, not all treatment failures with Fansidar
are necessarily due to plasmodial drug
resistance. The clinical efficacy of Fansidar has not
been 100%. A treatment failure rate of 15-20%
with Fansidar in field conditions had been observed
in several series. 16,17,18 Individual host factors may
be important; for example, failure of absorption or
rapid metabolism of the drug. However, acetylator
221phenotype had not been shown to be
important. 19.20 Even with adequate serum and
erythrocytic drug levels, treatment failure had been
documented in one case of drug-sensitive
falciparum infection. 21 Other undetermined host
erythrocytic factors must be responsible.
No in vitro test for Fansidar-resistant
Plasmodium is yet available to confirm the
presumptive clinical suspicion of drug resistance as
has been the case with chloroquine resistance.
Thus, in lieu ofsuch in vitro confirmatory testing, a
program of periodic clinical sampling as in this
study to monitor the treatment failure rate to
Fansidar would provide an indirect measure of the
trend ofFansidar resistance in P. falciparum,
The finding of 17.5% treatment failure in
patients with falciparum malaria diagnosed at
Tawau Hospital in 1982, three years after extensive
use of Fansidar, is consistent with previously
published results of the expected treatment failure
rate with Fansidar and does not suggest significant
drug resistance.
Furthermore, of interest is the fact that of the 7
patients with initial treatment failure, 6 responded
to retreaternent. This could be attributed to various
factors like lower parasitemia at the time of
retreatment; delayed drug absorption with initially
low serum concentration, rapid drugmetabolism or
partial drug resistance which was overcome by
higher drug levels after retreatment (since the half-
life ofsulfadoxine is 168 hours). Thus only 1 patient
with falciparum malaria in this studymay have true
Fansidar resistance.
This study suffered a serious weakness in that of
the original 110 consecutive patients diagnosed of
falciparum malaria, up to 45% defaulted all follow
up. It cannot be determined whether they were
more or less likely to harbour Fansidar-resistant
malaria. However, it seems that the patients
defaulted follow up because of socio-geographical
reasons rather than for reason oftheir illness.
Perhaps the patients who came to the hospital for
treatment of malaria had more "resistant" illness
than those who visited the camp clinics, health
centres and general practitioners in the
community. However, this could not be ascertained
from the study.
We have shown that only 18% acknowledged
having taken Fansidar on their own before coming
to the hospital, and most of them responded to
supervised treatment. The antecedent use of
Fansidar did not necessarily predispose to
treatment failure.
CONCLUSION
Despite the uncertainties inherent in this kind of
field study, the treatment failure rate of 17.5%
remains a reasonable baseline estimate for future
comparisons in similar clinical trials.
As it will take time for drug-resistant malaria to
spread, a program of periodic monitoring of the
rate of clinical treatment failure would provide a
practical method for detecting the appearance of
drug resistance.
In particular, since this study had established a
baseline level of treatment failure of Fansidar
treated falciparum malaria in Tawau Hospital,
Sabah, further periodic monitoring at Tawau
should be established as part of the routine services
of the local Malaria Office there towards this
purpose.
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